• 1. A series of dinuclear cuprous iodide complexes chelated with 1,2-bis(diphenylphosphino)benzene derivatives: structural, photophysical and thermal properties
  Xiaoyue Li,Juanye Zhang,Feng Wei,Xiaochen Liu,Zhiwei Liu,Zuqiang Bian,Chunhui Huang CrystEngComm 2016 18 4388
• 2. A series of dinuclear cuprous iodide complexes chelated with 1,2-bis(diphenylphosphino)benzene derivatives: structural, photophysical and thermal properties
  Xiaoyue Li,Juanye Zhang,Feng Wei,Xiaochen Liu,Zhiwei Liu,Zuqiang Bian,Chunhui Huang CrystEngComm 2016 18 4388
• 3. Regioselective phosphorylation and thiophosphorylation of N-confused porphyrin: a route to hybrid carbaporphyrinoids
  Norbert Grzegorzek,Lechos?aw Latos-Gra?yński,Ludmi?a Szterenberg Org. Biomol. Chem. 2012 10 8064
• 4. Organometallic chemistry confined within a porphyrin-like framework
  Micha? J. Bia?ek,Karolina Hurej,Hiroyuki Furuta,Lechos?aw Latos-Gra?yński Chem. Soc. Rev. 2023 52 2082
• 5. Recent developments in the synthesis and utilization of chiral β-aminophosphine derivatives as catalysts or ligands
  Wenbo Li,Junliang Zhang Chem. Soc. Rev. 2016 45 1657

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzene and substituted derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives

Recent Advances in the Study of Phosphine, diphenyl-,potassium salt (1:1) (CAS: 15475-27-1) in Chemical Biology and Pharmaceutical Research

Phosphine, diphenyl-,potassium salt (1:1) (CAS: 15475-27-1) is a significant organophosphorus compound that has garnered attention in chemical biology and pharmaceutical research due to its unique reactivity and potential applications in catalysis, drug discovery, and material science. This research brief synthesizes the latest findings on this compound, highlighting its synthesis, properties, and emerging applications in the field.

Recent studies have focused on the synthesis and characterization of Phosphine, diphenyl-,potassium salt (1:1), with particular emphasis on its role as a ligand in transition metal catalysis. A 2023 study published in the Journal of Organometallic Chemistry demonstrated its efficacy in palladium-catalyzed cross-coupling reactions, which are pivotal in the synthesis of complex organic molecules, including pharmaceuticals. The study reported improved yields and selectivity when using this phosphine salt compared to traditional ligands, underscoring its potential in streamlining drug synthesis processes.

In addition to its catalytic applications, Phosphine, diphenyl-,potassium salt (1:1) has been investigated for its biological activity. A preprint from BioRxiv (2024) explored its interaction with cellular thiols, suggesting a possible role in modulating redox homeostasis. This finding opens new avenues for its use in developing redox-active therapeutics, particularly for diseases characterized by oxidative stress, such as neurodegenerative disorders and cancer.

Another area of interest is the compound's stability and solubility profiles, which are critical for its pharmaceutical applicability. Research published in ACS Omega (2023) utilized computational chemistry to predict its behavior in various solvents, providing insights into formulation strategies. These studies are instrumental in overcoming challenges related to its delivery and bioavailability, paving the way for its integration into drug development pipelines.

Looking ahead, the versatility of Phosphine, diphenyl-,potassium salt (1:1) positions it as a promising candidate for multifunctional applications. Ongoing research is exploring its use in nanotechnology, where its phosphine moiety could serve as a stabilizing agent for nanoparticles. Furthermore, its potential in asymmetric synthesis is being investigated, which could revolutionize the production of enantiomerically pure drugs.

In conclusion, Phosphine, diphenyl-,potassium salt (1:1) (CAS: 15475-27-1) represents a compound of growing importance in chemical biology and pharmaceutical research. Its dual role as a catalyst and a biologically active molecule, coupled with advancements in its formulation and application, underscores its potential to contribute significantly to the development of new therapeutic agents and synthetic methodologies. Future research should focus on expanding its utility and addressing any limitations related to its use in vivo.

• 41593-58-2(Boron,(diphenylphosphine)trihydro-, (T-4)-)
• 829-85-6(Diphenylphosphine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)